Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins

Gene Therapy

Volumn 5, Issue 6, 1998, Pages 770-777

  Whittington, H A ^a,b   Ashworth, L J ^a   Hawkins, R E ^a  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Fusion; mGM CSF; Recombinant adenovirus; Single chain Fv

Indexed keywords

ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HAPTEN; HYBRID PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE THERAPY; HUMAN; HUMAN CELL; INTRAVENOUS ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; MURINAE;

EID: 0031828981     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300685     Document Type: Article

References (39)

1. Chester KA, Hawkins RE. Opportunities with phage technology and antibody engineering of fusion proteins. Adv Drug Del Rev 1996; 22: 303-314.
2. Chester KA, Hawkins RE, Clinical issues in antibody design. T1BTECH 1995; 13: 294-300.
3. Huston JS et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Eschericliia coli. Proc Nail Acad Sci USA 1988; 85: 5879-5883.
4. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Anna Rev Immwiol 1994; 12: 433-455.
5. Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity: mimicking affinity maturation. J Mol Biol 1992; 226: 889-896.
6. Chester KA et al. Phage libraries for generation of clinically useful antibodies. Lancet 1994; 343: 455-456.
7. Verhaar MJ et al. A single chain Fv derived from a filamentous phage library has distinct tumour targeting advantages over one derived from a hybridoma. Int J Cancer 1995; 61: 497-501.
8. Begent RHJ et al. Single-chain Fv antibody selected from a combinatorial library: clinical evidence of efficient tumour targeting. Nature Med 1996; 2: 979-984.
9. Savage P, So A, Spooner RA, Epenetos AA. A recombinant single chain antibody interleukin-2 fusion protein. Br J Cancer 1993; 67: 304-310.
10. Hornick JL et al. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Blood 1997; 89: 4437-4447.
11. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
12. Lee CT et al. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 1997; 8: 187-193.
13. Stevenson FK et al. Idiotypic DNA vaccines against B cell lymphoma. Immunol Rev 1995; 145: 211-228.
14. Malik N et al. Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. Mol Cell Biol 1989; 9: 2847-2853.
15. Hardy S et al. Construction of adenovirus vectors through Crelox recombination. J Virol 1997; 71: 1842-1849.
16. Michou AI et al. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Therapy 1997; 4: 473-482.
17. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802-8806.
18. Kozarsky KF et al. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Client 1994; 269: 13695-13702.
19. Colcher D et al. In vivo tumor targeting of a recombinant singlechain antigen-binding protein. J Natl Cancer Inst 1990; 82: 1191-1197.
20. Yang Y et al. Cellular immunity to viral antigens limits Eldeleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
21. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-6200.
22. Smith TA et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402.
23. Zabner J et al. Safety and efficacy of repetitive adenovirusmediated transfer of CFTR cDNTA to airway epithelia of primates and cotton rats. Nat Genet 1994; 6: 75-83.
24. Lei D et al. Nondepleting anti-CD4 antibody treatment prolongs lung-directed El-deleted adenovirus-mediated gene expression in rats. Hum Gene Ther 1996; 7: 2273-2279.
25. Jooss K, Yang Y, Wilson JM. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 1996; 7: 1555-1566.
26. Kay MA et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191-197.
27. Kochanek S et al. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and -galactosidase. Proc Nail Acad Sci USA 1996; 93: 5731-5736.
28. Fisher KJ et al. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 1996; 217: 11-22.
29. Chen HH et al. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 1997; 94:1645-1650.
30. Hu SX et al. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor a gene expression. Cancer Res 1997; 57: 3339-3343.
31. Agha-Mohammedi S, Hawkins RE. Efficient transgene regulation from a single tetracycline-controlled positive feedback regulatory system. Gene Therapy 1998; 5: 76-84.
32. Mack ÇA et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997; 8: 99-109.
33. Liu Y et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol 1997; 15: 167-173.
34. Rothmann T et al. Heart muscle-specific gene expression using replication defective recombinant adenovirus. Gene Therapy 1996; 3: 919-926.
35. VVatkins SJ, Mesyanzhinov W, Kurochkina LP, Hawkins RE. The adenobody approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Tlierapy 1997; 4: 1004-1012.
36. Hawkins RE, Winter G. Cell selection strategies for making antibodies from variable gene libraries: tapping the memory pool. Eur J Immunol 1992; 22: 867-870.
37. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. CeH 1986; 44: 283-292.
38. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354.
39. Dexter TM et al. Growth of factor-dependent hemopoietic precursor cell lines. J Exp Med 1980; 152: 1036-1047.